HERON THERAPEUTICS, INC. /DE/ (HRTX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US4277461020
HERON THERAPEUTICS, INC. /DE/ financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 154.90 m USD |
| Gross profit | 113.56 m USD |
| Operating income | -2.54 m USD |
| EBIT | -12.54 m USD |
| Net income | -20.20 m USD |
| Diluted EPS – continuing operations | -0.12 USD |
Full history since 1987, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About HERON THERAPEUTICS, INC. /DE/
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. Heron Therapeutics, Inc. was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. The company was founded in 1983 and is headquartered in Cary, North Carolina.
More stocks
- Complex Micro Interconnection Co. Ltd. (6835.TW)
- Camus Engineering & Construction Inc (013700.KS)
- AMCON DISTRIBUTING CO (DIT)
- Vizsla Copper Corp (VCU.V)
- Savezone I C (067830.KS)
- PYXUS INTERNATIONAL, INC. (PYYX)
- EISO Enterprise Co Ltd (5291.TWO)
- meerecompany Incorporated (049950.KQ)
- Protech Mitra Perkasa Tbk PT (OASA.JK)
- Advanced Lithium Electrochemistry Cayman Co Ltd (5227.TWO)
- Sturgis Bancorp Inc (STBI)
- BTL Inc. (6840.TWO)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.